BioCardia Inc logo

BCDA - BioCardia Inc News Story

$4.34 -0.1  -2.0%

Last Trade - 09/04/21

Small Cap
Market Cap £51.7m
Enterprise Value £36.1m
Revenue £106k
Position in Universe 5428th / 6827

BioCardia Announces Clinical Leadership Changes

Wed 17th February, 2021 1:30pm
For best results when printing this announcement, please click on link below:

SAN CARLOS, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc.
( [Nasdaq:
BCDA] a leader in the development of comprehensive solutions for
cardiovascular regenerative therapies, today announced clinical leadership

Dr. Sujith Shetty who has been with the Company for almost two years in the
capacity of Vice President of Clinical and Regulatory will assume the role of
Chief Medical Officer, replacing Dr. Eric Duckers, who resigned as Chief
Medical Officer of the Company to pursue other opportunities, effective as of
February 15th, 2021. Simultaneous with his resignation, Dr. Duckers entered
into a consulting agreement to continue to provide support for the ongoing
CardiAMP Heart Failure Trial and its leadership team.

Ms. Debby Holmes-Higgin who has been with the Company for more than three
years will continue to serve as Vice President of Clinical with expanded

Both Dr. Shetty and Ms. Holmes-Higgin will be supported by Dr. Hans-Peter
Stoll, who recently assumed the role of consulting Medical Monitor for the
CardiAMP clinical study. Dr. Stoll has extensive clinical experience having
been most recently the Chief Medical Officer at Biosensors International, GE
Healthcare, and Cordis, Johnson & Johnson.

“Evolution of the clinical team after the recent successful Data Safety
Monitoring Board Review of the CardiAMP Heart Failure Trial is an important
step for the success of the ongoing trial,” said Peter Altman, Ph.D.,
BioCardia’s President and CEO. “Dr. Shetty and Ms. Holmes-Higgin are world
class executives in whom we have every confidence, and I am delighted that
they will be supported both by Dr. Stoll as Medical Monitor and Dr. Duckers on
a consulting basis.”

About BioCardia®

BioCardia, Inc.
headquartered in San Carlos, California, is developing regenerative biologic
therapies to treat cardiovascular and respiratory disease. CardiAMP autologous
and Neurokinin-1 Receptor Positive allogenic cell therapies are the
Company’s biotherapeutic platforms in clinical development. The Company's
products include the Helix Biotherapeutic Delivery System and its steerable
guide and sheath catheter portfolio. BioCardia also partners with other
biotherapeutic companies to provide its Helix system and clinical support for
their programs studying therapies for the treatment of heart failure, chronic
myocardial ischemia, and acute myocardial infarction. For more information,

Forward Looking Statements:
This press release contains forward-looking statements that are subject to
risks and uncertainties. Forward-looking statements include statements
regarding our intentions, beliefs, projections, outlook, analyses or current

We may use terms such as “believes,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should,” “approximately” or other words that
convey the uncertainty of future events or outcomes to identify these
forward-looking statements. These forward-looking statements reflect our view
as of the time such statement is made and are not guarantees of future
performance or developments. Actual results and events may differ materially
from information contained in the forward-looking statements. BioCardia
expressly disclaims any intent or obligation to update these forward-looking
statements, except as required by law.

David McClung, Chief Financial Officer
(650) 226-0120

Michelle McAdam, Chronic Communications, Inc.
(310) 545-6654


GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.